1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Trials In Focus: A Call For Incentives To Help Drive Trial Diversity

 
• By Alaric DeArment

Panelists at the BIO CEO & Investor meeting talked about ways to improve trial diversity. Also, GSK and Pfizer released retrospective analyses of diversity in their trials, while J&J is working to improve diversity with Stand Up To Cancer.

• Source: Shutterstock

The Food and Drug Omnibus Reform Act, signed at the end of 2022 amid heightened attention to the importance of clinical trials enrolling diverse populations, requires clinical trial sponsors to submit “diversity action plans” for late-stage drug and device studies. But panelists at the recent BIO CEO & Investor Conference suggested more needs to happen for diversity to become the norm, including an effort by the entire health care sector and incentives to encourage diversity.

“I think a lot of this is going to come back to what are the economic incentives that we’ll try to sustain commitment to representation in trials,” Decentralized Trials & Research Alliance co-chair Craig Lipset said on the 6 February panel

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

More from R&D

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.